Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Celsa

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Liver Cancer|October 9, 2025
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse StudyAlessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Liver Cancer|October 9, 2025
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse StudyAlessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, et al.
Pageof 12